Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > No posts for over a month
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(90)
•••
Comment by TheTruth1234on Nov 10, 2023 10:37am
104 Views
Post# 35728286

RE:RE:RE:RE:RE:No posts for over a month

RE:RE:RE:RE:RE:No posts for over a month
Boomskid wrote: I agree. She's following the scenario you say, TheTruth1234, and the one I described over two years ago - do nothing, let Bioasis whither, join a private entity that acquires the xB3 Platform, and make lottsa moolah for herself so she might choose to live offshore and freeload off of taxpayers. I'm sure you understand how that works, TT.

How hard was it for me to track things down, TT?




LMAO Johnny boy!
 
Yes sirree Bob!! Rathjen is going to "make lottsa moolah for herself" on a technology every Pharmaceutical company passed on!!
 
Yup. You nailed it Johnny boy.
 
 
Must be all that "readn' and studyn' the internet" you do!!
 
The Scientists and Oncologists who passed on a dud, just couldn't "connect the dots" like you can!!!!
 
 
LMFAO
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities